logo
Researchers develop brain training game for chronic nerve pain

Researchers develop brain training game for chronic nerve pain

Hans India3 days ago

New Delhi: Australian researchers have developed a new interactive game, showing early promise as a non-invasive, drug-free alternative for managing chronic nerve pain.
The project, called PainWaive, trains users to regulate abnormal brain activity linked to neuropathic pain, Xinhua news agency reported.
Developed by researchers from the University of New South Wales (UNSW), the game uses a headset to monitor brainwaves in real time while players engage with a mobile game that rewards healthy brainwave patterns, offering a potential home-based replacement for painkillers such as opioids.
Three out of four participants reported significant pain reduction after four weeks of use in a recent trial. Their relief was comparable to or greater than what is typically achieved with opioid medication, the team found.
The game is based on disrupted brainwave activity in people with nerve pain, particularly changes in the thalamus -- a key relay centre in the brain.
The technology helps users retrain abnormal brain activity using mental strategies like relaxation or positive imagery, said Sylvia Gustin, professor at UNSW. The findings are published in the Journal of Pain.
'Participants felt empowered to manage their pain in their own environment. That's a huge part of what makes this special,' said Dr Negin Hesam-Shariati from UNSW's NeuroRecovery Research Hub.
Participants used a low-cost EEG (electroencephalogram) headset and tablet-based game at home, with remote monitoring by researchers.
Designed using 3D printing and open-source parts, the headset costs around $193.7, far cheaper than commercial systems, and uses wet electrodes to target the brain's sensorimotor cortex for accurate pain-related readings, PainWaive's design prioritises accessibility for those with limited access to conventional treatments, Gustin said. She added that recruitment is underway for two larger trials targeting chronic spinal pain and neuropathic pain from spinal cord injuries.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A second Australian IVF mix-up shakes clinic and industry
A second Australian IVF mix-up shakes clinic and industry

Time of India

timea day ago

  • Time of India

A second Australian IVF mix-up shakes clinic and industry

Bengaluru: One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's in a second fertility clinic mix-up, heightening concerns about an industry that did not have much active government oversight until recently. Monash IVF said the error took place on June 5 at a clinic in Melbourne but did not provide further details such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It said the patient's embryo was mistakenly implanted under a treatment plan which called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF, which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. "This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector," Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 25% by midsession on Tuesday, against a rising broader market. The stock is just over half its value before the April announcement. "We had thought the Brisbane clinic embryo transfer error was an isolated incident," Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. "We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations." Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said on Tuesday it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. It said it had reported the Melbourne incident to state regulator the Victorian Department of Health and industry licencing body the Reproductive Technology Accreditation Committee (RTAC), part of industry group the Fertility Society of Australia. Victorian health minister Mary-Anne Thomas said the department was investigating the company and the incident. "Families should have confidence that the treatment they are receiving is done to the highest standard," she said. "It is clear Monash IVF has failed to deliver that, which is completely unacceptable." Fertility Society president Petra Wale said the incident would have had an emotional toll on the family but stressed mistakes in the sector were rare. The society reiterated a call to implement nationally consistent laws around IVF. Currently, the country's IVF industry is regulated by a combination of industry bodies and state and territory health departments, resulting in a governance and compliance system that some groups say is too complex. Reports of transferring a wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind. ($1 = 1.5330 Australian dollars)

Global trial finds structured exercise cuts colon cancer deaths by 37 per cent
Global trial finds structured exercise cuts colon cancer deaths by 37 per cent

New Indian Express

timea day ago

  • New Indian Express

Global trial finds structured exercise cuts colon cancer deaths by 37 per cent

Professor Janette Vardy, international co-chair of the study and Senior Research Fellow at Sydney Medical School, said, 'Our findings will change the way we treat colon cancer.' 'Participants in the exercise program showed a significant improvement in disease-free survival compared to those who received only health education, currently the standard of care.' 'After eight years, those who exercised had a 90 per cent survival rate versus 83 per cent for the control group. This shows that exercise isn't just beneficial, it can be life‑saving. Something as simple as physical activity can vastly improve life expectancy and long-term outcomes for colon cancer survivors.' Dr. Christopher Booth, Medical Oncologist at Kingston Health Sciences Centre and study co-chair, said, 'The CHALLENGE (CO.21) trial provides an answer to the common patient question: what else can improve outcomes? An exercise program after surgery and chemotherapy reduces the risk of recurrent or new cancer and improves survival.' Professor Haryana Dhillon, Australian co-chair, stated, 'The average age of colon cancer patients is 68, and we targeted those not already meeting the recommended 150 minutes of moderate activity weekly. We personalized aerobic exercise plans based on individual preferences, making them both effective and sustainable.' Dr. Kerry Courneya, Canada Research Chair in Physical Activity and Cancer, said, 'Our study shows exercise is no longer just a quality-of-life component, it's a treatment that should be available to all colon cancer patients.' Professor Vardy urged the policymakers and health authorities to embed these findings into clinical guidelines. "We need equitable access to supported, structured exercise programs for cancer survivors. By positioning exercise alongside chemotherapy and surgery, we can dramatically improve outcomes," he said. In 2022, over one million people were diagnosed with colon cancer and more than half died from it. Recurrence is high: around 30% of people with stage III colon cancer experience a recurrence after treatment. In India, colon cancer ranks 13th in both incidence and mortality. Colon cancer often begins as small, noncancerous polyps, which can become cancerous if not detected and removed early. It is highly treatable and often curable when detected early and localized.

Australian Scientists Have Found A Way To Fight Superbug That Kills 10 Lakh Every Year
Australian Scientists Have Found A Way To Fight Superbug That Kills 10 Lakh Every Year

News18

time2 days ago

  • News18

Australian Scientists Have Found A Way To Fight Superbug That Kills 10 Lakh Every Year

Last Updated: Australian scientists at the Peter Doherty Institute developed Real-Time Genome Sequencing to combat Staphylococcus aureus, improving treatment precision and saving lives In a major global health breakthrough, Australian scientists have developed a revolutionary technology to outsmart one of the world's deadliest bacteria, Staphylococcus aureus, commonly known as 'Golden Staph'. This superbug, which claims nearly a million lives each year, has increasingly outwitted conventional antibiotics, forcing the medical world to search for smarter solutions. Now, researchers at Melbourne's Peter Doherty Institute for Infection and Immunity believe they may have found one. Their answer lies in a cutting-edge innovation called Real-Time Genome Sequencing, a technique that allows doctors to track the DNA of dangerous bacteria live, as the infection progresses within the patient's body. Unlike traditional lab tests that often only identify the bacteria species, this real-time sequencing goes several steps further: it pinpoints the exact genetic mutations, reveals how the bacteria is evolving, and identifies which antibiotics are likely to fail or succeed. This leap in diagnostic precision means that treatment decisions can now be based on hard genomic data, rather than educated guesswork. Doctors can adapt therapies instantly as the infection mutates, a key advantage when dealing with highly resistant bacteria like Golden Staph. The results of the study, recently published in Nature Communications, are striking. The technology was trialed across seven Melbourne hospitals. Researchers found that in nearly one-third of Golden Staph infection cases, the bacteria mutated during the course of treatment, rendering previously effective drugs useless. In one particularly alarming case, a patient who appeared to recover relapsed shortly after stopping medication. When the infection returned, the bacteria had become 80 times more powerful. Thanks to real-time sequencing, clinicians were able to identify this sudden mutation early and swiftly alter the treatment plan, ultimately saving the patient's life. The success of the project is now paving the way for a global first. Hospitals across Victoria are preparing to launch the world's first clinical genomic service, integrating this real-time technology into routine care for patients with severe, drug-resistant infections. This innovation could not be more timely. The World Health Organisation (WHO) has already warned that if antibiotic resistance continues to grow unchecked, superbugs could cause up to 10 million deaths annually by 2050, surpassing the current global toll of cancer. Golden Staph is one of the biggest culprits, notorious for infecting wounds, lungs, and even the bloodstream, often in hospital settings. 'This is not just a scientific advancement, it's a crucial tool in the global fight against antimicrobial resistance," said one of the lead researchers at the Doherty Institute. Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated! First Published:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store